Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients
Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC.
(WRAL Tech Wire)
Related: Campus Connections
UNC Connections to the Stanley Cup Champion Carolina HurricanesMike Sundheim has been with the Carolina Hurricanes in some capacity for 28 years. Sundheim graduated from UNC in 2000, meaning he started with the...
Thu Jun 25, 2026Take a closer look at South Building’s new copper roof
The weathervane at the top of South Building hasn’t been the highest point on campus in nearly a century, but for now, anyway, it is...
Wed Jun 24, 2026
UNC ranked No. 55 among universities across the world
The University of North Carolina is the 55th best school in the world, according to U.S. News. Carolina’s best subject areas, according to the rankings,...
Tue Jun 23, 2026
Student-owned coffee shop The Grounds opens on Franklin Street
The best word to describe the past month of UNC students Emily Lutgring and Allison Travis' lives is synchronicity. In the fall, both Lutgring, 20,...
Sat Jun 20, 2026